Click here to get full coverage on Mineralys Therapeutics (MLYS) Projected to Post Earnings on Wednesday - MarketBeat

Mineralys Therapeutics (MLYS) Projected to Post Earnings on Wednesday  MarketBeat

Mineralys Therapeutics (MLYS) Projected to Post Earnings on Wednesday - MarketBeat

Click here to get full coverage on Mineralys schedules first-quarter 2026 results call for May 6 - Stock Titan

Mineralys schedules first-quarter 2026 results call for May 6  Stock Titan

Mineralys schedules first-quarter 2026 results call for May 6 - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer - Yahoo Finance

Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer  Yahoo Finance

Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer - Yahoo Finance

Click here to get full coverage on TD Cowen initiates coverage of Mineralys Therapeutics (MLYS) with buy recommendation - MSN

TD Cowen initiates coverage of Mineralys Therapeutics (MLYS) with buy recommendation  MSN

TD Cowen initiates coverage of Mineralys Therapeutics (MLYS) with buy recommendation - MSN

Click here to get full coverage on TD Cowen Initiates Mineralys Therapeutics(MLYS.US) With Buy Rating - Moomoo

TD Cowen Initiates Mineralys Therapeutics(MLYS.US) With Buy Rating  Moomoo

TD Cowen Initiates Mineralys Therapeutics(MLYS.US) With Buy Rating - Moomoo

Click here to get full coverage on Mineralys Therapeutics (NASDAQ:MLYS) Trading 8.2% Higher - Should You Buy? - MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Trading 8.2% Higher - Should You Buy?  MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Trading 8.2% Higher - Should You Buy? - MarketBeat

Click here to get full coverage on Congleton, Mineralys Therapeutics CEO, sells $421k in MLYS stock - Investing.com

Congleton, Mineralys Therapeutics CEO, sells $421k in MLYS stock  Investing.com

Congleton, Mineralys Therapeutics CEO, sells $421k in MLYS stock - Investing.com

Click here to get full coverage on (MLYS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

(MLYS) Price Dynamics and Execution-Aware Positioning  Stock Traders Daily

(MLYS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Click here to get full coverage on Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback - Yahoo Finance

Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback  Yahoo Finance

Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback - Yahoo Finance

Click here to get full coverage on Mineralys Therapeutics, Inc. $MLYS Shares Bought by Jennison Associates LLC - MarketBeat

Mineralys Therapeutics, Inc. $MLYS Shares Bought by Jennison Associates LLC  MarketBeat

Mineralys Therapeutics, Inc. $MLYS Shares Bought by Jennison Associates LLC - MarketBeat

Click here to get full coverage on Mineralys CEO sells 15,730 shares under 10b5-1 plan | MLYS Insider Trading - Stock Titan

Mineralys CEO sells 15,730 shares under 10b5-1 plan | MLYS Insider Trading  Stock Titan

Mineralys CEO sells 15,730 shares under 10b5-1 plan | MLYS Insider Trading - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones - Yahoo Finance

Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones  Yahoo Finance

Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones - Yahoo Finance

Click here to get full coverage on Mineralys (MLYS) CMO exercises options and sells 20,406 shares in 10b5-1 trades - Stock Titan

Mineralys (MLYS) CMO exercises options and sells 20,406 shares in 10b5-1 trades  Stock Titan

Mineralys (MLYS) CMO exercises options and sells 20,406 shares in 10b5-1 trades - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's Why - MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's Why  MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's Why - MarketBeat

Click here to get full coverage on Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy? - Yahoo Finance

Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy?  Yahoo Finance

Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy? - Yahoo Finance

Click here to get full coverage on Mineralys (MLYS) CMO logs small 10b5-1 share sale and option exercise - Stock Titan

Mineralys (MLYS) CMO logs small 10b5-1 share sale and option exercise  Stock Titan

Mineralys (MLYS) CMO logs small 10b5-1 share sale and option exercise - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress - Yahoo Finance

Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress  Yahoo Finance

Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress - Yahoo Finance

Click here to get full coverage on Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Yahoo Finance

Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension  Yahoo Finance

Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Yahoo Finance

Click here to get full coverage on Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance

Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback?  Yahoo Finance

Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance

Click here to get full coverage on Mineralys Therapeutics (MLYS) Rule 144: Director sales and 2,170-share cashless exercise - Stock Titan

Mineralys Therapeutics (MLYS) Rule 144: Director sales and 2,170-share cashless exercise  Stock Titan

Mineralys Therapeutics (MLYS) Rule 144: Director sales and 2,170-share cashless exercise - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (MLYS) CMO Rodman sold $548k in shares - Investing.com

Mineralys Therapeutics (MLYS) CMO Rodman sold $548k in shares  Investing.com

Mineralys Therapeutics (MLYS) CMO Rodman sold $548k in shares - Investing.com

Click here to get full coverage on 416-share cashless exercise reported by Mineralys (NASDAQ: MLYS) - Stock Titan

416-share cashless exercise reported by Mineralys (NASDAQ: MLYS)  Stock Titan

416-share cashless exercise reported by Mineralys (NASDAQ: MLYS) - Stock Titan

Click here to get full coverage on Affiliate sale of 14,058 shares and multiple David Rodman trades (MLYS) - Stock Titan

Affiliate sale of 14,058 shares and multiple David Rodman trades (MLYS)  Stock Titan

Affiliate sale of 14,058 shares and multiple David Rodman trades (MLYS) - Stock Titan

Click here to get full coverage on A Look At Mineralys Therapeutics (MLYS) Valuation After FDA Accepts Lorundrostat NDA For Hypertension - simplywall.st

A Look At Mineralys Therapeutics (MLYS) Valuation After FDA Accepts Lorundrostat NDA For Hypertension  simplywall.st

A Look At Mineralys Therapeutics (MLYS) Valuation After FDA Accepts Lorundrostat NDA For Hypertension - simplywall.st

Click here to get full coverage on Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $422,035.90 in Stock - MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $422,035.90 in Stock  MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $422,035.90 in Stock - MarketBeat

Click here to get full coverage on Mineralys (MLYS) CMO exercises options and sells 2,170 shares under 10b5-1 plan - Stock Titan

Mineralys (MLYS) CMO exercises options and sells 2,170 shares under 10b5-1 plan  Stock Titan

Mineralys (MLYS) CMO exercises options and sells 2,170 shares under 10b5-1 plan - Stock Titan

Click here to get full coverage on Insider Sale: Chief Medical Officer of $MLYS Sells 70,037 Shares | MLYS Stock News - Quiver Quantitative

Insider Sale: Chief Medical Officer of $MLYS Sells 70,037 Shares | MLYS Stock News  Quiver Quantitative

Insider Sale: Chief Medical Officer of $MLYS Sells 70,037 Shares | MLYS Stock News - Quiver Quantitative

Click here to get full coverage on Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - Yahoo Finance

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak  Yahoo Finance

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - Yahoo Finance

Click here to get full coverage on David Rodman sells shares; Mineralys Therapeutics (NASDAQ: MLYS) Form 144 listing - Stock Titan

David Rodman sells shares; Mineralys Therapeutics (NASDAQ: MLYS) Form 144 listing  Stock Titan

David Rodman sells shares; Mineralys Therapeutics (NASDAQ: MLYS) Form 144 listing - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (NASDAQ: MLYS) insider sales and RSU vesting disclosed - Stock Titan

Mineralys Therapeutics (NASDAQ: MLYS) insider sales and RSU vesting disclosed  Stock Titan

Mineralys Therapeutics (NASDAQ: MLYS) insider sales and RSU vesting disclosed - Stock Titan

Click here to get full coverage on MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

MLYS Stock Price and Chart — NASDAQ:MLYS  TradingView

MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

Click here to get full coverage on $MLYS stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

$MLYS stock is up 13% today. Here's what we see in our data.  Quiver Quantitative

$MLYS stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on New blood pressure drug shows promise for hard-to-treat patients - Stock Titan

New blood pressure drug shows promise for hard-to-treat patients  Stock Titan

New blood pressure drug shows promise for hard-to-treat patients - Stock Titan

Click here to get full coverage on Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan

Biotech Mineralys offers 4-year stock awards to new hires  Stock Titan

Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan

Click here to get full coverage on Price-Driven Insight from (MLYS) for Rule-Based Strategy - Stock Traders Daily

Price-Driven Insight from (MLYS) for Rule-Based Strategy  Stock Traders Daily

Price-Driven Insight from (MLYS) for Rule-Based Strategy - Stock Traders Daily

Click here to get full coverage on MLYS Price Today: Mineralys Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

MLYS Price Today: Mineralys Therapeutics, Inc. Stock Price, Quote & Chart | MEXC  MEXC Exchange

MLYS Price Today: Mineralys Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Click here to get full coverage on Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint - Trefis

Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint  Trefis

Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint - Trefis

Click here to get full coverage on Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections - Stock Titan

Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections  Stock Titan

Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections - Stock Titan

Click here to get full coverage on Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans - Yahoo Finance

Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans  Yahoo Finance

Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans - Yahoo Finance

Click here to get full coverage on Blood pressure drug wins FDA review as apnea study shows no gain - Stock Titan

Blood pressure drug wins FDA review as apnea study shows no gain  Stock Titan

Blood pressure drug wins FDA review as apnea study shows no gain - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares - Stock Titan

Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares  Stock Titan

Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares - Stock Titan

Click here to get full coverage on Mineralys spikes as blood pressure drug undergoes FDA review - Seeking Alpha

Mineralys spikes as blood pressure drug undergoes FDA review  Seeking Alpha

Mineralys spikes as blood pressure drug undergoes FDA review - Seeking Alpha

Click here to get full coverage on Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares - Stock Titan

Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares  Stock Titan

Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares - Stock Titan

Click here to get full coverage on Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires? - simplywall.st

Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires?  simplywall.st

Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires? - simplywall.st

Click here to get full coverage on Mineralys Therapeutics CEO Congleton sells $529k in MLYS stock - Investing.com

Mineralys Therapeutics CEO Congleton sells $529k in MLYS stock  Investing.com

Mineralys Therapeutics CEO Congleton sells $529k in MLYS stock - Investing.com

Click here to get full coverage on Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan

Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares  Stock Titan

Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan

Click here to get full coverage on Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha

Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS)  Seeking Alpha

Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha

Click here to get full coverage on RA Capital funds add 369,000 Mineralys (NASDAQ: MLYS) shares - Stock Titan

RA Capital funds add 369,000 Mineralys (NASDAQ: MLYS) shares  Stock Titan

RA Capital funds add 369,000 Mineralys (NASDAQ: MLYS) shares - Stock Titan

Click here to get full coverage on Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock - Investing.com

Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock  Investing.com

Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock - Investing.com

Click here to get full coverage on Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial - Yahoo Finance

Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial  Yahoo Finance

Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial - Yahoo Finance

Click here to get full coverage on New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan

New Mineralys hire gets stock options and RSUs vesting over four years  Stock Titan

New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan

Click here to get full coverage on Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k - Stock Titan

Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k  Stock Titan

Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k - Stock Titan

Click here to get full coverage on Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha

Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS)  Seeking Alpha

Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha

Click here to get full coverage on Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan

Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions  Stock Titan

Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan

Click here to get full coverage on Mineralys therapeutics MLYS: Chief medical officer sells $59k in shares - Investing.com

Mineralys therapeutics MLYS: Chief medical officer sells $59k in shares  Investing.com

Mineralys therapeutics MLYS: Chief medical officer sells $59k in shares - Investing.com

Click here to get full coverage on Did New Phase 3 Results and FDA Milestones Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative? - Yahoo Finance

Did New Phase 3 Results and FDA Milestones Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?  Yahoo Finance

Did New Phase 3 Results and FDA Milestones Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative? - Yahoo Finance

Click here to get full coverage on Mineralys (MLYS) Q4 2025 Earnings Call Transcript - The Globe and Mail

Mineralys (MLYS) Q4 2025 Earnings Call Transcript  The Globe and Mail

Mineralys (MLYS) Q4 2025 Earnings Call Transcript - The Globe and Mail

Click here to get full coverage on Mineralys Trial Recognition Highlights NDA Path And Dilution Considerations - Yahoo Finance

Mineralys Trial Recognition Highlights NDA Path And Dilution Considerations  Yahoo Finance

Mineralys Trial Recognition Highlights NDA Path And Dilution Considerations - Yahoo Finance

Click here to get full coverage on Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - Yahoo Finance

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug  Yahoo Finance

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - Yahoo Finance

Click here to get full coverage on Mineralys Therapeutics Q4 Earnings Call Highlights - Yahoo Finance

Mineralys Therapeutics Q4 Earnings Call Highlights  Yahoo Finance

Mineralys Therapeutics Q4 Earnings Call Highlights - Yahoo Finance

Click here to get full coverage on Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update  Yahoo Finance

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

Click here to get full coverage on Mineralys Therapeutics (MLYS) Stock: Why Pricing Increase (Idled) 2026-04-18 - Small Cap Breakout - Cổng thông tin điện tử Tỉnh Sơn La

Mineralys Therapeutics (MLYS) Stock: Why Pricing Increase (Idled) 2026-04-18 - Small Cap Breakout  Cổng thông tin điện tử Tỉnh Sơn La

Mineralys Therapeutics (MLYS) Stock: Why Pricing Increase (Idled) 2026-04-18 - Small Cap Breakout - Cổng thông tin điện tử Tỉnh Sơn La

Click here to get full coverage on Mineralys Therapeutics, Inc. (MLYS): An 85.82% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews

Mineralys Therapeutics, Inc. (MLYS): An 85.82% Potential Upside Sparks Investor Interest  DirectorsTalk Interviews

Mineralys Therapeutics, Inc. (MLYS): An 85.82% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews

Click here to get full coverage on Mineralys Therapeutics MLYS CMO sells shares worth $542,973 - Investing.com

Mineralys Therapeutics MLYS CMO sells shares worth $542,973  Investing.com

Mineralys Therapeutics MLYS CMO sells shares worth $542,973 - Investing.com

Click here to get full coverage on Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions (MLYS) - Seeking Alpha

Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions (MLYS)  Seeking Alpha

Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions (MLYS) - Seeking Alpha

Click here to get full coverage on Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 - Yahoo Finance

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026  Yahoo Finance

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 - Yahoo Finance

Click here to get full coverage on $MLYS stock is up 87% today. Here's what we see in our data. - Quiver Quantitative

$MLYS stock is up 87% today. Here's what we see in our data.  Quiver Quantitative

MLYS

Price Chart

Key Statistics

Technicals

About MLYS

Latest News

Mineralys Therapeutics (MLYS) Projected to Post Earnings on Wednesday - MarketBeat

Mineralys schedules first-quarter 2026 results call for May 6 - Stock Titan

Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers